Subject: RE: Report May 2017 (Georgia C Elimination program)
From: "Graeme Robertson" <[email-masked]>
To: Aysan Murtezaoglu <[email-masked]>; Irinka Tskhomelidze <[email-masked]>
Cc: David Sergeenko;
Date: Thu, 1 Jun 2017 11:03:57 +0000

Thank you  Irinka, appreciate the May report.

Best wishes

Graeme

Graeme.A Robertson

Senior Director,  Africa & CIS

Access Operations & Emerging Markets

--------------------------------------------------------------------------------------------------------------------------------------------------

Gilead Sciences Europe Ltd
• Registered as a limited company in England and Wales • Registered number
05510315

Registered office:
South Building • 2 Roundwood Avenue • Stockley Park • Uxbridge • UB11 1AZ • England

Telephone:
+44(0)208 587 2228
• Mobile: +44(0)7789 268 043 • Fax:
+44(0)208 744 6773

From: Aysan Murtezaoglu

Sent: 01 June 2017 10:28

To: Irinka Tskhomelidze; Graeme Robertson

Cc: David Sergeenko

Subject: RE: Report May 2017 (Georgia C Elimination program)

Hi Irina

Thank you for the May report. The mandatory screening for me aged 30-50 seems like a good idea to find out more positive patients.

Best regards

Aysan

From: Irinka Tskhomelidze [mailto:[email-masked]]

Sent: 01 June 2017 10:33

To: Graeme Robertson; Aysan Murtezaoglu

Cc: David Sergeenko

Subject: Report May 2017 (Georgia C Elimination program)

Dear Graeme and Aysan,

Hope this Email finds you well and thank you once again for your assistance which always leads to the success of the program, support to our country is really
appreciated.

Attached please find a report for the current month (May 2017).

Thank you.

--

Best regards,

Irina Tskhomelidze,

Health Care Department

Ministry of Labour, Health and Social Affairs of Georgia

DISCLAIMER If you have received this message in error, please contact the sender immediately by return e-mail and notify the sender and then delete this message (including any attachments) from your system. This communication and any attachments contain information
which is confidential and may also be legally privileged. It is for the exclusive use of the intended recipient(s). If you are not the intended recipient(s) please note that any form of disclosure, distribution, copying or use of this communication or the
information in it or in any attachments is strictly prohibited and may be unlawful. E-mail communications cannot be guaranteed to be secure or error free, as information could be intercepted, corrupted, amended, lost, destroyed, arrive late or incomplete,
or contain viruses. Gilead does not accept liability for any such matters or their consequences. Anyone who communicates with Gilead by e-mail is taken to accept the risks in doing so. Gilead has taken every reasonable precaution to ensure that any attachment
to this e-mail has been swept for viruses. However, Gilead cannot accept liability for any damage sustained as a result of viruses and would advise that you carry out your own virus checks before opening any attachment. Gilead Sciences Europe Ltd ; Registered
as a limited company in England and Wales ; Registered number 5510315 Registered office: South Building ; 2 Roundwood Avenue ; Stockley Park ; Uxbridge ; UB11 1AF ; England